MET and renal carcinoma: Dysregulation of the c-MET/MET pathway occurs through various mechanisms, including gene amplification, mutation, rearrangement, and protein overexpression, and has been reported to be involved in different cancers, including NB, NSCLC (non-small cell lung cancer), colorectal, ovarian, breast, gastric, and renal cancers [6,12].